Silence Therapeutics (NASDAQ:SLN) Issues Quarterly Earnings Results

Silence Therapeutics (NASDAQ:SLN) issued its earnings results on Thursday. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.13), FiscalAI reports. Silence Therapeutics had a negative return on equity of 106.94% and a negative net margin of 8,943.86%.

Silence Therapeutics Trading Up 0.0%

Shares of NASDAQ:SLN traded up $0.01 during trading on Thursday, hitting $19.77. 188,961 shares of the stock were exchanged, compared to its average volume of 1,092,224. The company has a fifty day moving average price of $14.46 and a two-hundred day moving average price of $9.61. The company has a market cap of $1.23 billion, a PE ratio of -15.45 and a beta of 1.34. Silence Therapeutics has a 12-month low of $4.19 and a 12-month high of $19.86.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on SLN. Weiss Ratings reiterated a “sell (d-)” rating on shares of Silence Therapeutics in a research report on Thursday, October 15th. HC Wainwright cut Silence Therapeutics from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $75.00 to $20.00 in a research note on Wednesday, October 21st. Morgan Stanley boosted their price objective on Silence Therapeutics from $25.00 to $32.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 11th. William Blair downgraded shares of Silence Therapeutics from an “outperform” rating to a “hold” rating in a research report on Monday, October 19th. Finally, Jefferies Financial Group lowered shares of Silence Therapeutics from a “buy” rating to a “hold” rating and set a $20.00 target price on the stock. in a research report on Monday, October 19th. Two investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $24.00.

Silence Therapeutics Company Profile

Silence Therapeutics is a biotechnology company developing medicines based on RNA interference (RNAi), a biological process that can reduce production of specific disease-related proteins. Its proprietary mRNAi GOLD platform is designed to create small interfering RNA (siRNA) medicines, including treatments that target genes expressed in the liver. The company’s research and development programs have included zerlasiran, which targets lipoprotein(a), a risk factor for cardiovascular disease, and divesiran, investigated for blood disorders.